Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

Patient-Derived Follicular Lymphoma Tumoroids: A Tool to Recapitulate Biological Features of Low and High-Grade Lymphoma

Ruben Gimenez, Neus Serrat, Miquel Castellote-Borrell, Victor Jiménez-Martínez, Eduardo Pérez del Río, Mireia Bachiller, Ferran Araujo-Ayala, Raul F Pérez, Ares Martínez-Farran, Jose Ángel Robles, Armando Lopez-Guillermo, Elias Campo, Josep Villanueva, Sonia Guedan, Jose Ignacio Martin-Subero, Judith Guasch, Daniel J Hodson, Dolors Colomer, Patricia Pérez Galán

Blood (2024) 144 (Supplement 1): 1613.

https://doi.org/10.1182/blood-2024-198454

Published: 2024

Journal Articles

CD70 Deregulation in Follicular Lymphoma at Diagnosis Is Associated with Relapse and Opens New Avenues for Dual CD19-CD70 CAR-T Therapy

Blood (2024) 144 (Supplement 1): 333.

https://doi.org/10.1182/blood-2024-199167

Published: 2024

Journal Articles

Utility of Baseline PET/CT As Surrogate of Molecular Features in Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 6222.

https://doi.org/10.1182/blood-2024-205717

Published: 2024

Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Blood (2023) 142 (Supplement 1): 3085.

https://doi.org/10.1182/blood-2023-174081

Published: 2023

Journal Articles

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Blood (2023) 142 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2023-186594

Published: 2023

Journal Articles

A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21 R110

Blood (2022) 140 (Supplement 1): 1800–1802.

https://doi.org/10.1182/blood-2022-165181

Published: 2022

Journal Articles

Immunocompetent 3D Follicular Lymphoma Model: A Preclinical Tool to Design Tailored Immunotherapies

Cèlia Dobaño-López, Juan G Valero, Ferran Araujo-Ayala, Ferran Nadeu, Fabien Gava, Carla Faria, Marine Norlund, Renaud Morin, Pascale Bernes-Lasserre, Neus Serrat, Heribert Playa-Albinyana, Andrea Rivero, Pablo Mozas, Elías Campo, Jean-Michel Lagarde, Armando López-Guillermo, Dolors Colomer, Christine Bezombes, Patricia Pérez-Galán

Blood (2022) 140 (Supplement 1): 9279–9280.

https://doi.org/10.1182/blood-2022-166131

Published: 2022

Journal Articles

Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL-112)

Juan-Manuel Sancho, Pau Abrisqueta, Abhijeet Kumar, Raul Cordoba, Monica Tani, Teng Liu, Erica Rappold, Peter Langmuir, Armando Lopez-Guillermo

Blood (2022) 140 (Supplement 1): 9328–9330.

https://doi.org/10.1182/blood-2022-159703

Published: 2022

Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Max S. Topp, Monica Tani, Michael Dickinson, Nilanjan Ghosh, Armando Santoro, Antonio Pinto, Francesc Bosch, Christopher P. Fox, Armando López-Guillermo, Claudia Carlucci, Chun Wu, Kathryn Humphrey, Pauline Baumlin, Martin Barrett, Naseer Qayum, Franck Morschhauser

Blood (2022) 140 (Supplement 1): 1775–1777.

https://doi.org/10.1182/blood-2022-157732

Published: 2022

Journal Articles

Combination of Ibrutinib and Nivolumab Overcomes Ibrutinib Resistance in a Novel Patient-Derived Mantle Cell Lymphoma 3D Model

Ferran Araujo-Ayala, Cèlia Dobaño-López, Juan G Valero, Ferran Nadeu, Fabien Gava, Carla Faria, Marine Norlund, Renaud Morin, Pascale Bernes-Lasserre, Neus Serrat, Heribert Playa-Albinyana, Rubén Giménez, Elías Campo, Jean Michel Lagarde, Armando López-Guillermo, Eva Giné, Dolors Colomer, Christine Bezombes, Patricia Pérez-Galán

Blood (2022) 140 (Supplement 1): 1323–1324.

https://doi.org/10.1182/blood-2022-163381

Published: 2022

Journal Articles

Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Blood (2022) 140 (Supplement 1): 9347–9349.

https://doi.org/10.1182/blood-2022-160073

Published: 2022

Journal Articles

Development of a Novel Chromatin Activation Score As a Powerful Independent Prognostic Factor in Chronic Lymphocytic Leukemia

Vicente Chapaprieta, Alba Maiques-Diaz, Guillem Clot, Ferran Nadeu, Judith Mateos-Jaimez, Anna Vidal, Stella Charalampopoulou, Martí Duran-Ferrer, Romina Royo, Junyan Lu, Thorsten Zenz, Julio Delgado, Armando Lopez-Guillermo, Elías Campo, José I. Martín-Subero

Blood (2022) 140 (Supplement 1): 4123–4124.

https://doi.org/10.1182/blood-2022-158919

Published: 2022

Journal Articles

Whole-Genome Analysis of Histone Modifications Reveals New Insights into the Biology and Clinical Behavior of Mantle Cell Lymphoma Subtypes

Beatriz García-Torre, Marta Kulis, Mònica Romo, Anna Vidal, Stella Charalampopoulou, Vicente Chapaprieta, Martí Duran-Ferrer, Ferran Nadeu, Cristina López, Guillem Clot, Eva Giné, Armando Lopez-Guillermo, Sílvia Beà, Dolors Colomer, Elías Campo, José I. Martín-Subero

Blood (2022) 140 (Supplement 1): 1745–1746.

https://doi.org/10.1182/blood-2022-163085

Published: 2022

Journal Articles

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla-Martinez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Dogan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesus San-Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana Advani, Stephen Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando Lopez-Guillermo, Maria Victoria Mateos, Elizabeth Macintyre, Ari M. Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano A. Pileri, Miguel Piris, Barbara Pro, Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier-Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz

Blood (2022) 140 (11): 1229–1253.

https://doi.org/10.1182/blood.2022015851

Published: 2022

Includes: Supplemental data

Journal Articles

Genetic and phenotypic attributes of splenic marginal zone lymphoma

Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Valeria Spina, Adalgisa Condoluci, Luisella Bonomini, Gabriela Forestieri, Ricardo Koch, Deborah Piffaretti, Katia Pini, Maria Cristina Pirosa, Micol Giulia Cittone, Alberto Arribas, Marco Lucioni, Guido Ghilardi, Wei Wu, Luca Arcaini, Maria Joao Baptista, Gabriela Bastidas, Silvia Bea, Renzo Boldorini, Alessandro Broccoli, Marco Matteo Buehler, Vincenzo Canzonieri, Luciano Cascione, Luca Ceriani, Sergio Cogliatti, Paolo Corradini, Enrico Derenzini, Liliana Devizzi, Sascha Dietrich, Angela Rita Elia, Fabio Facchetti, Gianluca Gaidano, Juan Fernando Garcia, Bernhard Gerber, Paolo Ghia, Maria Gomes da Silva, Giuseppe Gritti, Anna Guidetti, Felicitas Hitz, Giorgio Inghirami, Marco Ladetto, Armando Lopez-Guillermo, Elisa Lucchini, Antonino Maiorana, Roberto Marasca, Estella Matutes, Veronique Meignin, Michele Merli, Alden Moccia, Manuela Mollejo, Carlos Montalban, Urban Novak, David Graham Oscier, Francesco Passamonti, Francesco Piazza, Stefano Pizzolitto, Alessandro Rambaldi, Elena Sabattini, Gilles Salles, Elisa Santambrogio, Lydia Scarfò, Anastasios Stathis, Georg Stüssi, Julia T. Geyer, Gustavo Tapia, Corrado Tarella, Catherine Thieblemont, Thomas Tousseyn, Alessandra Tucci, Giorgio Vanini, Carlo Visco, Umberto Vitolo, Renata Walewska, Francesco Zaja, Thorsten Zenz, Pier Luigi Zinzani, Hossein Khiabanian, Arianna Calcinotto, Francesco Bertoni, Govind Bhagat, Elias Campo, Laurence De Leval, Stefan Dirnhofer, Stefano A. Pileri, Miguel A. Piris, Alexandra Traverse-Glehen, Alexander Tzankov, Marco Paulli, Maurilio Ponzoni, Luca Mazzucchelli, Franco Cavalli, Emanuele Zucca, Davide Rossi

Blood (2022) 139 (5): 732–747.

https://doi.org/10.1182/blood.2021012386

Published: 2022

Includes: Supplemental data

Journal Articles

SOX11, CD70, and T reg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma

Patricia Balsas, Luis Veloza, Guillem Clot, Marta Sureda-Gómez, Marta-Leonor Rodríguez, Christos Masaoutis, Gerard Frigola, Alba Navarro, Silvia Beà, Ferran Nadeu, Eva Giné, Armando López-Guillermo, Antonio Martínez, Inmaculada Ribera-Cortada, Pablo Engel, Leticia Quintanilla-Martínez, Wolfram Klapper, Elias Campo, Virginia Amador

Blood (2021) 138 (22): 2202–2215.

https://doi.org/10.1182/blood.2020010527

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

Blood (2021) 138 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2021-148431

Published: 2021

Journal Articles

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Blood (2021) 138 (Supplement 1): 2417.

https://doi.org/10.1182/blood-2021-148218

Published: 2021

Journal Articles

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Blood (2021) 138 (Supplement 1): 2497.

https://doi.org/10.1182/blood-2021-148361

Published: 2021

Journal Articles

Infection Risk in Lymphoproliferative Diseases (LPD) Treated with Targeted Drugs. Geltamo Real-Life Experience

Blood (2020) 136 (Supplement 1): 37–40.

https://doi.org/10.1182/blood-2020-134729

Published: 2020

NARROW

Patient-Derived Follicular Lymphoma Tumoroids: A Tool to Recapitulate Biological Features of Low and High-Grade Lymphoma

CD70 Deregulation in Follicular Lymphoma at Diagnosis Is Associated with Relapse and Opens New Avenues for Dual CD19-CD70 CAR-T Therapy

Utility of Baseline PET/CT As Surrogate of Molecular Features in Mantle Cell Lymphoma

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21 R110

Immunocompetent 3D Follicular Lymphoma Model: A Preclinical Tool to Design Tailored Immunotherapies

Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL-112)

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Combination of Ibrutinib and Nivolumab Overcomes Ibrutinib Resistance in a Novel Patient-Derived Mantle Cell Lymphoma 3D Model

Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Development of a Novel Chromatin Activation Score As a Powerful Independent Prognostic Factor in Chronic Lymphocytic Leukemia

Whole-Genome Analysis of Histone Modifications Reveals New Insights into the Biology and Clinical Behavior of Mantle Cell Lymphoma Subtypes

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Genetic and phenotypic attributes of splenic marginal zone lymphoma

SOX11, CD70, and T reg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma

A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo

Infection Risk in Lymphoproliferative Diseases (LPD) Treated with Targeted Drugs. Geltamo Real-Life Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only